{"id":"NCT04184622","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight","officialTitle":"Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-04","primaryCompletion":"2022-04-01","completion":"2024-07-06","firstPosted":"2019-12-03","resultsPosted":"2023-04-24","lastUpdate":"2025-07-24"},"enrollment":2539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Overweight","Obesity"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"5 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"10 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"}],"summary":"This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.","primaryOutcome":{"measure":"Percent Change From Baseline in Body Weight (Primary Treatment Period)","timeFrame":"Baseline, Week 72","effectByArm":[{"arm":"Placebo","deltaMin":-2.4,"sd":0.4},{"arm":"5 mg Tirzepatide","deltaMin":-16,"sd":0.39},{"arm":"10 mg Tirzepatide","deltaMin":-21.4,"sd":0.39},{"arm":"15 mg Tirzepatide","deltaMin":-22.5,"sd":0.39}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":118,"countries":["United States","Argentina","Brazil","China","India","Japan","Mexico","Puerto Rico","Russia","Taiwan"]},"refs":{"pmids":["40717199","40677091","40550133","40512543","39800653","39536238","39497468","39084707","37700443","35658024"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/1o8ZY82Yn01Z4Hqvx0WuME"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":643},"commonTop":["Nausea","Covid-19","Diarrhoea","Constipation","Dyspepsia"]}}